Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial

Abstract This phase Ib study compared the effects of AZD9977, a selective mineralocorticoid receptor modulator with predicted low hyperkalemia risk, with spironolactone on serum potassium (sK+) in patients with heart failure (HF) with preserved or mildly reduced ejection fraction (EF; ≥40%), and ren...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Iain B. Squire, Anders Gabrielsen, Peter J. Greasley, Linda Wernevik, Judith Hartleib‐Geschwindner, Julie Holden, Susanne Johansson, Anna Rudvik, José Sánchez, Krister Bamberg, Johanna Melin, Andrew Whittaker
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2022-10-01
Colecção:	Clinical and Translational Science
Acesso em linha:	https://doi.org/10.1111/cts.13377
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!